Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer.

Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Levêque J, Jézéquel P, Campion L, Campone M, Ducret T, MacGrogan G, Debure L, Collette Y, Vacher P, Legembre P.

Cancer Res. 2020 Feb 1;80(3):639. doi: 10.1158/0008-5472.CAN-19-3636. No abstract available.

2.

Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence.

Dumont F, Joseph S, Lorimier G, De Franco V, Wernert R, Verriele V, Kerdraon O, Campion L, Capitain O, Guerin-Meyer V, Raimbourg J, Senellart H, Hiret S, Raoul JL, Thibaudeau E.

Surg Oncol. 2020 Mar;32:23-29. doi: 10.1016/j.suronc.2019.10.018. Epub 2019 Nov 4.

PMID:
31707314
3.

Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.

Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F.

Prostate. 2019 Sep;79(13):1514-1522. doi: 10.1002/pros.23869. Epub 2019 Aug 17.

PMID:
31421657
4.

Reoxygenation during radiotherapy in intermediate-risk prostate cancer.

Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D.

Radiother Oncol. 2019 Apr;133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12.

PMID:
30935573
5.
6.

The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).

Pérol D, Robain M, Arveux P, Mathoulin-Pélissier S, Chamorey E, Asselain B, Berchery D, Gourgou S, Breton M, Delaine-Clisant S, Mons M, Diéras V, Carton M, Guizard AV, Laborde L, Laurent C, Loeb A, Mouret-Reynier MA, Parent D, Perrocheau G, Campion L, Velten M, Cailliot C, Ezzalfani M, Simon G.

BMJ Open. 2019 Feb 21;9(2):e023568. doi: 10.1136/bmjopen-2018-023568.

7.

Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).

Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X, De Laroche G, Beckendorf V, Sargos P, Créhange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Campion L, Supiot S.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1061-1067. doi: 10.1016/j.ijrobp.2018.12.020. Epub 2018 Dec 14.

8.

68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.

Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C.

Prostate. 2019 Apr;79(5):454-461. doi: 10.1002/pros.23751. Epub 2018 Dec 14.

PMID:
30549066
9.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Bennouna J, André T, Campion L, Hiret S, Miglianico L, Mineur L, Touchefeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.

Clin Colorectal Cancer. 2019 Mar;18(1):e69-e73. doi: 10.1016/j.clcc.2018.09.011. Epub 2018 Oct 19.

PMID:
30415988
10.

[Early phase trials at the "Institut de cancérologie de l'Ouest": Clinical outcome and validation of prognostic scores].

Greilsamer C, Campion L, Cabart M, Gourmelon C, Senellart H, Bennouna J.

Bull Cancer. 2018 Oct;105(10):896-906. doi: 10.1016/j.bulcan.2018.05.016. Epub 2018 Jun 29. French.

PMID:
30348261
11.

Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.

Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L.

Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20.

PMID:
30343457
12.

Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer.

Fleury V, Ferrer L, Colombié M, Rusu D, Le Thiec M, Kraeber-Bodéré F, Campion L, Rousseau C.

Oncotarget. 2018 Aug 3;9(60):31744-31752. doi: 10.18632/oncotarget.25860. eCollection 2018 Aug 3.

13.

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.

Bompas E, Campion L, Italiano A, Le Cesne A, Chevreau C, Isambert N, Toulmonde M, Mir O, Ray-Coquard I, Piperno-Neumann S, Saada-Bouzid E, Rios M, Kurtz JE, Delcambre C, Dubray-Longeras P, Duffaud F, Karanian M, Le Loarer F, Soulié P, Penel N, Blay JY.

Cancer Med. 2018 Aug;7(8):4023-4035. doi: 10.1002/cam4.1374. Epub 2018 Jun 28. Review.

14.

Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.

Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, Rio E, Milano GA, Mahier-Ait Oukhatar C, Carrie C.

Oncotarget. 2018 Apr 24;9(31):22147-22157. doi: 10.18632/oncotarget.25189. eCollection 2018 Apr 24.

15.

Model predicting the ypN0 status after good response to chemoradiotherapy in rectal cancer.

Dumont F, Dartigues P, Delga B, Thibaudeau E, Benhaim L, Campion L, Mosnier JF, Raimbourg J, Kerdraon O, Goéré D.

Am J Surg. 2018 Sep;216(3):438-443. doi: 10.1016/j.amjsurg.2018.03.025. Epub 2018 Mar 31.

PMID:
29656991
16.

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.

Goineau A, Campion L, d'Aillières B, Vié B, Ghesquière A, Béra G, Jaffres D, de Laroche G, Magné N, Artignan X, Chamois J, Bergerot P, Martin E, Créhange G, Deniaud-Alexandre E, Buthaud X, Belkacémi Y, Doré M, de Decker L, Supiot S.

PLoS One. 2018 Apr 9;13(4):e0194173. doi: 10.1371/journal.pone.0194173. eCollection 2018.

17.

Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.

Supiot S, Rousseau C, Dore M, Cheze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D.

Oncotarget. 2018 Jan 13;9(11):10005-10015. doi: 10.18632/oncotarget.24234. eCollection 2018 Feb 9.

18.

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS.

Breast Cancer Res Treat. 2018 Apr;168(2):559-566. doi: 10.1007/s10549-017-4623-8. Epub 2017 Dec 15.

PMID:
29247442
19.

Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.

Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C.

Oncotarget. 2017 Aug 18;8(44):77050-77060. doi: 10.18632/oncotarget.20335. eCollection 2017 Sep 29.

20.

Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.

Bailly C, Leforestier R, Campion L, Thebaud E, Moreau A, Kraeber-Bodere F, Carlier T, Bodet-Milin C.

PLoS One. 2017 Aug 25;12(8):e0183841. doi: 10.1371/journal.pone.0183841. eCollection 2017.

21.

Logic programming reveals alteration of key transcription factors in multiple myeloma.

Miannay B, Minvielle S, Roux O, Drouin P, Avet-Loiseau H, Guérin-Charbonnel C, Gouraud W, Attal M, Facon T, Munshi NC, Moreau P, Campion L, Magrangeas F, Guziolowski C.

Sci Rep. 2017 Aug 23;7(1):9257. doi: 10.1038/s41598-017-09378-9.

22.

Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer.

Voog E, Campion L, du Rusquec P, Bourgeois H, Domont J, Denis F, Emmanuel E, Dupuis O, Ganem G, Lafont C, Le Du K, Pavluc E, Pointreau Y, Roche S, Juhel-Voog L, Zinger M, Solal-Celigny P.

Support Care Cancer. 2018 Jan;26(1):81-89. doi: 10.1007/s00520-017-3816-3. Epub 2017 Jul 29.

PMID:
28756472
23.

Dynamic conformal arc radiosurgery for arteriovenous malformations: Outcome and influence of clinical and dosimetrical data.

Clement-Colmou K, Roualdes V, Martin SA, Josset S, Desal H, Campion L, Thillays F.

Radiother Oncol. 2017 May;123(2):251-256. doi: 10.1016/j.radonc.2017.03.013. Epub 2017 Mar 25.

PMID:
28351522
24.

Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes.

Jouglar E, Thomas L, de la Rochefordière A, Noël G, Le Blanc-Onfroy M, Delpon G, Campion L, Mahé MA.

Cancer Radiother. 2016 Dec;20(8):794-800. doi: 10.1016/j.canrad.2016.06.007. Epub 2016 Oct 26.

PMID:
28270323
25.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
26.

Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis.

Doré M, Martin S, Delpon G, Clément K, Campion L, Thillays F.

Cancer Radiother. 2017 Feb;21(1):4-9. doi: 10.1016/j.canrad.2016.06.010. Epub 2016 Dec 7.

PMID:
27955888
27.

High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study.

Pichon B, Campion L, Delpon G, Thillays F, Carrie C, Cellier P, Pommier P, Laude C, Mervoyer A, Hamidou H, Mahé MA, Supiot S.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):840-847. doi: 10.1016/j.ijrobp.2016.07.027. Epub 2016 Jul 30.

PMID:
27663759
28.

Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation.

Jouglar E, Wagner A, Delpon G, Campion L, Meingan P, Bernier V, Demoor-Goldschmidt C, Mahé MA, Lacornerie T, Supiot S.

PLoS One. 2016 Oct 20;11(10):e0164643. doi: 10.1371/journal.pone.0164643. eCollection 2016.

29.

Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Clin Colorectal Cancer. 2016 Dec;15(4):e165-e174. doi: 10.1016/j.clcc.2016.04.009. Epub 2016 May 7.

PMID:
27256668
30.

Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study.

Renaudeau C, Lefebvre-Lacoeuille C, Campion L, Dravet F, Descamps P, Ferron G, Houvenaeghel G, Giard S, Tunon de Lara C, Dupré PF, Fritel X, Ngô C, Verhaeghe JL, Faure C, Mezzadri M, Damey C, Classe JM.

Breast. 2016 Aug;28:54-9. doi: 10.1016/j.breast.2016.04.006. Epub 2016 May 20.

PMID:
27214241
31.

Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.

Rousseau C, Rousseau T, Mathieu C, Lacoste J, Potiron E, Aillet G, Nevoux P, Le Coguic G, Campion L, Kraeber-Bodéré F.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1849-56. doi: 10.1007/s00259-016-3397-2. Epub 2016 May 11.

PMID:
27164901
32.

[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Bull Cancer. 2016 Jun;103(6):541-51. doi: 10.1016/j.bulcan.2016.03.007. Epub 2016 May 5. French.

PMID:
27155924
33.

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults.

Le Bourgeois A, Peterlin P, Guillaume T, Delaunay J, Duquesne A, Le Gouill S, Moreau P, Mohty M, Campion L, Chevallier P.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1473-1479. doi: 10.1016/j.bbmt.2016.04.015. Epub 2016 Apr 24.

34.

Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan.

Dubois N, Rio E, Ripoche N, Ferchaud-Roucher V, Gaugler MH, Campion L, Krempf M, Carrie C, Mahé M, Mirabel X, Paris F.

Radiother Oncol. 2016 May;119(2):229-35. doi: 10.1016/j.radonc.2016.03.014. Epub 2016 Apr 21.

35.

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.

Magrangeas F, Kuiper R, Avet-Loiseau H, Gouraud W, Guérin-Charbonnel C, Ferrer L, Aussem A, Elghazel H, Suhard J, Sakissian H, Attal M, C Munshi N, Sonneveld P, Dumontet C, Moreau P, van Duin M, Campion L, Minvielle S.

Clin Cancer Res. 2016 Sep 1;22(17):4350-4355. doi: 10.1158/1078-0432.CCR-15-3163. Epub 2016 Apr 8.

36.

Gene-expression signature functional annotation of breast cancer tumours in function of age.

Jézéquel P, Sharif Z, Lasla H, Gouraud W, Guérin-Charbonnel C, Campion L, Chrétien S, Campone M.

BMC Med Genomics. 2015 Nov 23;8:80. doi: 10.1186/s12920-015-0153-6.

37.

Intérêt de la technique isotopique du ganglion sentinelle associée aux outils préopératoires de prédiction du risque d'envahissement ganglionnaire dans le cancer de la prostate : à propos de 200 patients.

Rousseau T, Lacoste J, Potiron E, Le Coguic G, Nevoux P, Aillet G, Campion L, Rousseau C.

Prog Urol. 2014 Nov;24(13):785-6. doi: 10.1016/j.purol.2014.08.010. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461536
38.

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer.

Mathieu C, Ferrer L, Carlier T, Colombié M, Rusu D, Kraeber-Bodéré F, Campion L, Rousseau C.

Front Med (Lausanne). 2015 Sep 9;2:67. doi: 10.3389/fmed.2015.00067. eCollection 2015.

39.

OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F.

BMC Cancer. 2015 Sep 25;15:646. doi: 10.1186/s12885-015-1579-0.

40.

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.

Rusu D, Carlier T, Colombié M, Goulon D, Fleury V, Rousseau N, Berton-Rigaud D, Jaffre I, Kraeber-Bodéré F, Campion L, Rousseau C.

Front Med (Lausanne). 2015 Jul 22;2:46. doi: 10.3389/fmed.2015.00046. eCollection 2015.

41.

Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases.

Doré M, Cutuli B, Cellier P, Campion L, Le Blanc M.

Radiat Oncol. 2015 Aug 4;10:161. doi: 10.1186/s13014-015-0448-y.

42.

Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.

Campone M, Valo I, Jézéquel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, Guette C.

Mol Cell Proteomics. 2015 Nov;14(11):2936-46. doi: 10.1074/mcp.M115.048967. Epub 2015 Jul 24.

43.

Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.

Colombié M, Campion L, Bailly C, Rusu D, Rousseau T, Mathieu C, Ferrer L, Rousseau N, Kraeber-Bodéré F, Rousseau C.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1784-93. doi: 10.1007/s00259-015-3123-5. Epub 2015 Jul 21.

PMID:
26194716
44.

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verrièle V, Campone M.

Breast Cancer Res. 2015 Mar 20;17:43. doi: 10.1186/s13058-015-0550-y.

45.

[Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases].

Oger AS, Boukerrou M, Cutuli B, Campion L, Rousseau E, Bussières E, Raro P, Classe JM.

Gynecol Obstet Fertil. 2015 Apr;43(4):290-6. doi: 10.1016/j.gyobfe.2015.02.010. Epub 2015 Mar 26. French.

PMID:
25818033
46.

Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.

Bailly C, Eugène T, Couec ML, Strullu M, Frampas E, Campion L, Kraeber-Bodéré F, Bodet-Milin C.

Front Med (Lausanne). 2014 Dec 16;1:54. doi: 10.3389/fmed.2014.00054. eCollection 2014.

47.

Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study.

Yossi S, Krhili S, Muratet JP, Septans AL, Campion L, Denis F.

Clin Nucl Med. 2015 Apr;40(4):e215-21. doi: 10.1097/RLU.0000000000000615.

PMID:
25546211
48.

[Sexual functions after treatment for rectal cancer: impact of doses in autonomic pelvic nerves].

Goineau A, Mahé MA, Paineau J, Campion L, Rio E.

Cancer Radiother. 2014 Dec;18(8):757-62. doi: 10.1016/j.canrad.2014.10.005. Epub 2014 Nov 15. French.

PMID:
25457790
49.

Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue.

Goineau A, Piot B, Malard O, Ferron C, Lisbona A, Cassagnau E, Delamazure AS, Campion L, Bardet E.

Brachytherapy. 2015 Jan-Feb;14(1):71-6. doi: 10.1016/j.brachy.2014.09.011. Epub 2014 Nov 6.

PMID:
25454575
50.

[The elderly in radiotherapy: myths and prospects].

Goineau A, Campion L, Mahé MA.

Geriatr Psychol Neuropsychiatr Vieil. 2014 Sep;12(3):261-6. doi: 10.1684/pnv.2014.0485. French.

PMID:
25245312

Supplemental Content

Loading ...
Support Center